{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5fa6e32f007fe14c6dd46501/62c701de3c109c0012144bd0?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Pulmonary Exacerbations and IV Antibiotics","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5fa6e32f007fe14c6dd46501/1606931129949-7dcd8e4f19b4a46abf23069ff1fc7105.jpeg?height=200","description":"<p>Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care?&nbsp;&nbsp;</p><p>Join us for this&nbsp;<em>e</em>CysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explains how these questions can affect clinical care.&nbsp;</p><p><br></p><p>Take our&nbsp;<a href=\"https://elit.dkbmed.com/issues/143/test\" rel=\"noopener noreferrer\" target=\"_blank\">post-test</a>&nbsp;to claim CME credits.</p><p>Read this podcast's companion newsletter <a href=\"https://elit.dkbmed.com/issues/138\" rel=\"noopener noreferrer\" target=\"_blank\">here</a>.</p>","author_name":"eCysticFibrosis Review"}